Purpose:To redirect an ongoing antiviralT-cell response against tumor cells in vivo, we evaluated conjugates consisting of antitumor antibody fragments coupled to class I MHC molecules loaded with immunodominant viral peptides. Experimental Design: First, lymphochoriomeningitis virus (LCMV)^infected C57BL/6 mice were s.c. grafted on the right flank with carcinoembryonic antigen (CEA)^transfected MC38 colon carcinoma cells precoated with anti-CEA Â H-2D b /GP33 LCMV peptide conjugate and on the left flank with the same cells precoated with control anti-CEA F(ab ¶) 2 fragments. Second, influenza virus^infected mice were injected i.v., to induce lung metastases, with HER2-transfected B16F10 cells, coated with either anti-HER2 Â H-2D b /NP366 influenza peptide conjugates, or anti-HER2 F(ab ¶) 2 fragments alone, or intact anti-HER2 monoclonal antibody. Third, systemic injections of anti-CEA Â H-2D b conjugates with covalently cross-linked GP33 peptides were tested for the growth inhibition of MC38-CEA + cells, s.c. grafted in LCMV-infected mice.Results: In the LCMV-infected mice, five of the six grafts with conjugate-precoated MC38-CEA + cells did not develop into tumors, whereas all grafts with F(ab ¶) 2 -precoated MC38-CEA + cells did so (P = 0.0022). In influenza virus^infected mice, the group injected with cells precoated with specific conjugate had seven times less lung metastases than control groups (P = 0.0022 and P = 0.013). Most importantly, systemic injection in LCMV-infected mice of anti-CEA Â H-2D b /cross-linked GP33 conjugates completely abolished tumor growth in four of five mice, whereas the same tumor grew in all five control mice (P = 0.016).
Conclusion:The results show that a physiologic T-cell antiviral response in immunocompetent mice can be redirected against tumor cells by the use of antitumor antibody  MHC/viral peptide conjugates.In recent years, a major effort has been dedicated to the development of active vaccination protocols for immunotherapy of cancer patients, using newly discovered tumor-specific or differentiation antigens (1 -3). Successful induction of specific T-cell responses and tumor infiltration by T lymphocytes were well documented, but the number of tumor remissions remained low (4,5). It is hard to understand the reasons for the relatively poor antitumor activity of the induced specific T lymphocytes, given that such effector cells are known to be so efficient in the elimination of virus-infected cells and in allograft rejection. Three major explanations have been given for the inefficiency of the T-cell antitumor response: the poor antigenicity of autologous tumor antigens, the low expression or absence of MHC molecules on the tumor cell surface, or some functional defects in their antigen-processing machinery (6, 7).Here, we present a new immunotherapeutic strategy that has the potential to overcome these obstacles. We coupled an antitumor antibody fragment to an MHC molecule loaded with an immunodominant viral peptide and showed that tumor cells coated with the...